Baricitinib inhibits the intracellular signaling pathway of cytokines implicated in severe COVID-19, including IL-2, IL-6, IL-10, IFN-γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Here, CSF2 is linked to COVID-19.